Friday, February 10, 2012 Last update: 12:33 PM
The Best of U.S. Company Technology News

Maxim Pharmaceuticals Receives Recommendation from ISS in Favor of Proposed Merger with EpiCept Corporation

print this article - email to a friend - join our eNewsletter
Submitted by admin on 12/8/2005 @ 9:05 AM
Companies mentioned in this article: Maxim Pharmaceuticals

Maxim Pharmaceuticals, Inc. (NASDAQ:MAXM)(SSE:MAXM) announced today that the Institutional Shareholder Services, or ISS, has recommended that Maxim's stockholders vote in favor of the proposal to approve and adopt the merger agreement and the merger with EpiCept Corporation. ISS is a leading provider of proxy voting and corporate governance services to institutional investors, analyzing proxies and issuing informed research and objective vote recommendations for more than 33,000 companies across 115 markets worldwide.

The Company urges stockholders who have not already done so to vote their shares. Stockholders who have questions or need more information about the special meeting to be held on December 21, 2005, should contact the Company's proxy solicitor, MacKenzie Partners, as shown below.

EpiCept has filed a registration statement that contains a definitive proxy statement/prospectus with the Securities and Exchange Commission. STOCKHOLDERS OF MAXIM AND OTHER INVESTORS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THE PROXY STATEMENT/PROSPECTUS) REGARDING THE PROPOSED MERGER BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT EPICEPT, MAXIM AND THE PROPOSED MERGER. Maxim's stockholders may also obtain a free copy of the definitive proxy statement/prospectus, as well as other filings containing information about Maxim and EpiCept, without charge, at the SEC's Internet site (http://www.sec.gov). Copies of the proxy statement/prospectus and Maxim's other filings with the SEC can also be obtained, without charge, by directing a request to Maxim Pharmaceuticals, 8899 University Center Lane, Suite 400, San Diego, CA 92122, Attention: Investor Relations, Telephone: 858-453-4040 or MacKenzie Partners, Inc. toll free at 800-322-2885, or direct at 212-929-5500. If you are located in Sweden, you can call direct at +46-8-775-02-18.

PLEASE VOTE TODAY If you have any questions or need assistance in voting your proxy card, please contact our proxy solicitor MacKenzie Partners, Inc.

In North America: Call Toll Free - 800-322-2885 or call direct - 212-929-5500.

In Sweden: Call WM DATA direct +46-8-775-02-18

Stockholders in Sweden may also fax their proxy cards to WM DATA +46-8-775-01-95.

Swedish Shareholders may also vote through the Internet by logging on to www.maxim.com/sgm

You will find your password included on your proxy card recently mailed to you.

In Europe: Call direct +44-(0)-207-170-4155

Maxim Overview

Maxim is a biopharmaceutical company dedicated to developing innovative cancer therapeutics. Maxim has completed one Phase 3 clinical trial of Ceplene(TM) plus Interleukin-2 combination therapy as a remission maintenance therapy for patients with acute myeloid leukemia. Maxim is also engaged in the discovery and development of small-molecule apoptosis inducers and inhibitors to treat a wide range of disorders, including cancers and degenerative diseases. Using its proprietary high-throughput screening technology and its chemical genetics approach several lead compounds have been identified. Current efforts continue toward the development of these compounds either internally or through strategic collaborative arrangements.